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Abstract
Aim: To explore the roles of C-X-C chemokine receptor type 4 (CXCR4) in spinal processing of neuropathic pain at the
central nervous system (CNS).
Methods: Peripheral neuropathic pain (PNP) induced by partial sciatic nerve ligation (pSNL) model was assessed in mice.
Effects of a single intrathecal (central) administration of AMD3100 (intrathecal AMD3100), a CXCR4 antagonist, on pain
behavior and pain-related spinal pathways and molecules in the L3-L5 spinal cord segment was studied compare to saline
treatment.
Results: Rotarod test showed that intrathecal AMD3100 did not impair mice motor function. In pSNL-induced mice,
intrathecal AMD3100 delayed the development of mechanical allodynia and reversed the established mechanical allodynia
in a dose-dependent way. Moreover, intrathecal AMD3100 downregulated the activation of JNK1 and p38 pathways and the
protein expression of p65 as assessed by western blotting. Real-time PCR test also demonstrated that substance P mRNA
was decreased, while adrenomedullin and intercellular adhesion molecule mRNA was increased following AMD3100
treatment.
Conclusion: Our results suggest that central (spinal) CXCR4 is involved in the development and maintenance of PNP and the
regulation of multiple spinal molecular events under pain condition, implicating that CXCR4 would potentially be a
therapeutic target for chronic neuropathic pain.
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Introduction
Chemokine receptors have been intensively studied for their
roles in nociception and considered novel targets for neuropathic
pain therapy [1]. C-X-C chemokine receptor type 4 (CXCR4) is
the receptor of chemokine (C-X-C motif) ligand 12 (CXCL12),
which belongs to the G protein-coupled receptor (GPCR) family.
CXCR4 is widely expressed in the peripheral and central nervous
system (PNS and CNS) and exerts numerous important functions,
such as modulation of neurotransmission, synaptic plasticity, and
neuroglial interactions [2]. Increasing number of studies reported
roles of CXCR4 in pain processing in the PNS, as CXCR4 is
expressed on primary sensory neurons, satellite cells, Schwann
cells, and endothelial cells in the peripheral nociceptive structure
[3–9]. Recent immunohistochemistry studies also showed that
CXCR4 would be involved in the modulation of pain signaling in
the CNS. CXCL12 and CXCR4 were positive in neurons,
astrocytes, microglia/macrophages, and leukocytes in the lumbar
spinal cord and their spinal immunoreactivity was found to be
increased in a central neuropathic pain model [10]. The activation
of spinal CXCR4 by the intrathecal administration of CXCL12
has been found to induce mechanical allodynia for 3 days, which
could be reversed by a CXCR4-neutralizing antibody given
intrathecally [9].
Currently, systematic (intraperitoneal) administration of
CXCR4 antagonist, AMD3100, was demonstrated to have
analgesic effects on opioid-induced hyperalgesia [8] and neuro-
pathic pain induced by peripheral neuropathy [3] and by anti-
AIDS therapy [6,7]. These studies implicated the potential
application of AMD3100 for analgesia. However, central roles of
CXCR4 in pain transduction remain unclear and there has been
no study evaluating the effects of pharmacological inhibition of
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CXCR4 on central pain signal processing. Therefore, in this study,
we aimed to explore the roles and mechanisms of central CXCR4
in pain modulation using specific CXCR4 antagonist AMD3100
and a peripheral neuropathic pain (PNP) model using partial
sciatic nerve ligation (pSNL) in mice.
Materials and Methods
Animals
This research was approved by the Committee on the Use of
Live Animals in Teaching and Research (CULATR) (Permit
Number: 2610-11), the University of Hong Kong, and performed
according to the guidelines for the care and use of laboratory
animals as established by the Laboratory Animal Unit (LAU) at
the University of Hong Kong. The mice were housed at 2363uC,
with humidity ranges between 25% and 45% under a 12-hour
light/12-hour dark cycle (lights on at 07:00). The mice were
offered free access to water and food. They were fed with Lab Diet
5012 (1.0% calcium, 0.5% phosphorus, and 3.3 IU/g of vitamin
D3).
The experiments were conducted using adult male C57BL/6
wild-type mice (25–30 grams). Total number of mice used in this
project was 86. In Rotarod test, 20 mice that had not received any
operation or behavior test were randomly divided into four groups
(n=5 in each group). The mice of four groups were treated
intrathecally with AMD3100 1 mg (AMD3100 1 mg group), 5 mg
(AMD3100 5 mg group), 25 mg (AMD3100 25 mg group) or saline
(saline group). To study the roles of CXCR4 in the development of
PNP, the mice were randomly divided into four groups. Two
groups received either pSNL (pSNL group, n=6) or sham surgery
(sham group, n=6) without intrathecal drug administration. The
other two groups were treated 1 hour before pSNL surgery with a
single intrathecal injection of either AMD3100 (5 mg, AMD3100 +
pSNL group, n=12) or saline (saline + pSNL group, n=12). To
study the roles of CXCR4 in the maintenance of PNP, mice were
randomly divided into four groups, and all received pSNL surgery.
On post-operative day (POD) 7, four groups were treated with a
single intrathecal injection of AMD3100 or of saline. The dosages
given to the four groups were 1 mg (pSNL + AMD3100 1 mg
group, n=5), 5 mg (pSNL + AMD3100 5 mg group, n=6), 25 mg
(pSNL + AMD3100 25 mg group, n=6), or saline (pSNL + saline
group, n=5). To study the effects of a single intrathecal injection
of AMD3100 (intrathecal AMD3100) on pain pathways in the
lumbar spinal cords of pSNL-injured mice, the mice were treated
with a single injection of either AMD3100 25 mg (AMD3100
group) or saline (saline group) on POD 7 (n=8 per group). To
study the effects of intrathecal AMD3100 on pain molecules in the
lumbar spinal cords of pSNL-injured mice, the mice were treated
with a single injection of either AMD3100 25 mg (AMD3100
group) or saline (saline group) on POD 7 (n=6 per group).
Partial sciatic nerve ligation surgery
A pSNL surgery was used as the PNP model in this study [11].
The mice were anesthetized with halothane in a 1:1 mixture of O2
and N2O. Under aseptic conditions, the right sciatic nerve (SN)
was exposed by an incision from the right sciatic notch to the distal
thigh. The location of the SN ligation was identified using the
femoral head as a landmark. Approximately 1/2 of the SN was
tightly ligated with a 7-0 silk suture. In the sham-operated mice
that were used as controls, the right sciatic nerve was exposed, but
not ligated. The incision was closed with 5–0 cotton suture and
disinfected with ethanol.
Drug administration
AMD3100 (Sigma), a CXCR4 antagonist, was prepared in
saline on the day of the experiment. As the dosage of AMD3100
for intrathecal administration in mice has not been determined,
dosages of 1 mg, 5 mg, and 25 mg were used in this study.
AMD3100 was administrated as a single dose intrathecally,
according to a previous study [12]. Before the injection, the
animals were anesthetized using halothane with mixture of oxygen
and N2O as described above. Using a syringe (Hamilton) with a
30-gauge needle, a spinal cord puncture was made between the L3
and L5 levels in order to deliver a total volume of 5 ml to the
subarachnoid space. Successful administration was identified by
tail swinging or a tail configuration of the ‘‘S’’ type immediately
after injection.
von Frey test
Mechanical allodynia is the symptom of PNP, which is indicated
by a reduction in the paw withdrawal threshold (PWT). This
condition was assessed by von Frey test which was performed in
our previous research [13]. For habituation before the experiment,
the mice were placed in a transparent plastic dome with a metal
mesh floor for 20 to 30 minutes. Their PWT was measured with a
series of von Frey filaments (IITC). The filaments were applied
perpendicularly to the plantar surface of both hind paws, with
sufficient force to bend the filaments into an ‘‘S’’ shape. Quick
withdrawal or licking of the paw was considered a positive
response.
Rotarod test
To assess whether there would be any the potential side-effect of
a single intrathecal injection of AMD3100 (intrathecal AMD3100)
on motor function, a rotarod test was conducted to measure the
motor coordination and balance of the mice._ENREF_18 Twenty
mice that had not received any operation or behavior test were
randomly divided into four groups. These animals were habituated
to the rotarod apparatus (IITC) for 2 consecutive days at low-
speed rotation (5 rpm) for 600 seconds each day before basal
measurement. During the experiment, the animals were tested in
three accelerating trials of 300 seconds, with the rotarod speed
increasing from 5 to 40 rpm over 300 seconds, and with an inter-
trial interval of at least 20 minutes. The animals’ latency in falling
from the rod was recorded for each trial, with a cutoff time at 300
seconds.
Western blotting
The sciatic nerve of C57BL/6 mice is composed from elements
of L3 and L4 segments of spinal cord with a smaller contribution
from L5 segment [14]. Therefore, after euthanizing each mouse
with pentobarbital, the L3-L5 section of its spinal cord was quickly
removed and homogenized in ice-cold RIPA lysis buffer. After
concentration determination, protein samples were separated in
10% SDS-PAGE and electrotransferred onto PVDF membranes.
Protein samples were then probed with antibodies for extracellular
signal-regulated kinase (ERK, 4695, Cell Signaling), phosphory-
lated ERK (pERK, 4511, Cell Signaling), c-Jun N-terminal kinase
(JNK, 9258, Cell Signaling), phosphorylated JNK (pJNK, 4668,
Cell Signaling), p38 (9212, Cell Signaling), phosphorylated p38 (p-
p38, 4511, Cell Signaling), AKT (9272, Cell Signaling), phos-
phorylated AKT (pAKT, 4060, Cell Signaling), Signal transducer
and activator of transcription 3 (STAT3, 9132, Cell Signaling),
phosphorylated STAT3 (pSTAT3, 9131, Cell Signaling), or p65
(4764, Cell Signaling) with alpha-tubulin (T5168, Sigma) used as a
loading control. The membranes were visualized with horseradish
Central CXCR4 in Neuropathic Pain
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peroxidase (HRP)-conjugated secondary antibodies (anti-rabbit
IgG and anti-mouse IgG, Sigma).
Real time PCR
After euthanizing each mouse with pentobarbital, the L3-L5
section of its spinal cord was quickly removed and stored at 2
80uC until RNA extraction. mRNA was extracted from homog-
enized spinal cord segements following the manufacturer’s
protocol (Takara). After the quality and quantity determination,
mRNA samples were made to cDNA library with reverse
transcriptase (Life Technologies). Prepared cDNA samples were
diluted and stored at 220uC until further tests. Real time PCR
reactions were performed with the SYBR green chemistry method
or the Taqman chemistry method (Applied biosystems). The
specific primers for substance P (SP), adrenomedullin (AM),
calcitonin gene-related peptide (CGRP) and 18S rRNA were
reported in our previous study [13], and used with Fast SYBR
green master mix (Applied Biosystems). The Taqman Probes for
mouse Tumor necrosis factor-a (TNF-a, Mm00443258), interleu-
kin-1b (IL-1b, Mm00434228), interleukin-6 (IL-6, Mm00446190),
intercellular adhesion molecule (ICAM, Mm00516023), vascular
cell adhesion molecule (VCAM, Mm00449197), excitatory amino-
acid transporter-2 (EAAT-2, Mm00441457) and actin-b
(Mm01205647) were purchased from Applied Biosystems.
Statistical analysis
The data were expressed as means6 SEM. Student’s t tests was
used to analyze Western blot and real time PCR data. Results
from von Frey test was analyzed using a student’s t test or a two-
way analysis of variance (ANOVA), followed by a Tukey’s multiple
comparison post test. Results from the rotarod test were analyzed
using a two-way analysis of variance (ANOVA), followed by a
Tukey’s multiple comparison post test. In all cases, p,0.05 was
considered as statistically significant.
Results
Effects of intrathecal AMD3100 on the motor function of
mice
The effects of intrathecal AMD3100 on motor function had not
been studied before. Any impairment in motor function might
affect the assessment of pain and intrathecal AMD3100 would not
be suitable for potential analgesic treatment if that was the case.
Therefore, motor function after intrathecal AMD3100 was
assessed by a rotarod test in this study. The falling latency of the
three groups with intrathecal AMD3100 showed no significant
change compared to the saline group after the injection (p.0.05;
ANOVA; n= 5; Figure 1). These results indicated that intrathecal
AMD3100 did not influence the motor function of mice.
Effects of intrathecal AMD3100 on the development and
maintenance of mechanical allodynia in pSNL-injured
mice
AMD3100 or saline was given intrathecally at one hour before
pSNL surgery, and the involvement of central CXCR4 in the
development of PNP was evaluated by von Frey tests. Sham
surgery (n = 6) did not affect ipsilateral PWT, but pSNL surgery
(n = 6) decreased ipsilateral PWT significantly on POD 1 (p,
0.001; ANOVA). These results demonstrated that mechanical
allodynia was induced immediately by pSNL, but not by sham
operation. Pretreatment of a single intrathecal injection of saline
(intrathecal saline) did not have any effect on ipsilateral PWT in
Figure 1. The effects of intrathecal AMD3100 on the motor function of normal mice. There was no significant change in falling latency
among the three groups with intrathecal AMD3100, compared to the saline group from hour 1 to day 3 after the injection. Results are mean 6 SEM
(n=5). Sec. = second, D = day, Hr = hour, 0 = time of intrathecal injection.
doi:10.1371/journal.pone.0104860.g001
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the pSNL + saline group (n= 12), as compared with that in the
pSNL group without any intrathecal medication (p.0.05;
ANOVA). However, intrathecal AMD3100 before pSNL surgery
increased ipsilateral PWT significantly from day 1 to day 3 (p,
0.001; ANOVA; n= 12) after drug injection, as compared with the
pSNL + saline group (Figure 2A). No difference in contralateral
PWT was found among the four study groups (p.0.05; ANOVA;
Figure 2B). These results suggested that intrathecal AMD3100
could delay the development of mechanical allodynia by pSNL.
To study the role of central CXCR4 in the maintenance of
PNP, pSNL-injured mice received either intrathecal AMD3100 or
intrathecal saline on POD 7. Mechanical allodynia from hour 1 to
day 14 after the injection was assessed by von Frey test. Intrathecal
AMD3100 1 mg increased ipsilateral PWT from hour 1 to day 2
(p,0.01 or 0.05; student’s t test; n = 5; Figure 2C) after the
injection. Intrathecal AMD3100 5 mg increased ipsilateral PWT
from hour 1 to day 3 (p,0.001 or 0.01 or 0.05; student’s t test;
n = 6; Figure 2C) after the injection. Intrathecal AMD3100 25 mg
increased ipsilateral PWT from hour 1 to day 3 (p,0.001 or 0.05;
student’s t test; n = 6; Figure 2C) after the injection. Intrathecal
saline did not have any effect on ipsilateral PWT (p.0.05;
student’s t test; n = 5; Figure 2C). No significant difference was
shown in contralateral PWT among any of the four groups (p.
0.05; student’s t test; Figure 2D). These results suggested that
intrathecal AMD3100 could transiently reverse established
mechanical allodynia by pSNL in a dose-dependent way.
Effects of intrathecal AMD3100 on the production of pain
molecules in the lumbar spinal cord of pSNL-injured mice
Following the peripheral nerve injury, the central release of
neuropeptides (e.g. SP, CGRP and AM), pro-inflammatory
cytokines (e.g. TNF-a, IL-1b and IL-6), cellular adhesion
molecules (e.g. ICAM and VCAM) and glutamate transporter
(e.g. EAAT-2) contribute to neuronal central sensitization and
persistent pain [15,16]. Therefore, we also investigated whether
intrathecal AMD3100 could affect the spinal production of these
neuropeptides and pro-inflammatory cytokines. The mRNA level
of SP was decreased but the mRNA level of AM and ICAM were
increased significantly on the ipsilateral side of the L3-L5 spinal
cord segment in pSNL-injured mice with intrathecal AMD3100
25 mg (n= 6) compared to the saline group (n= 6) at 8 hour after
the injection (p,0.05; student’s t test; Figures 3B, C and G).
However, the mRNA levels of CGRP, TNF-a, IL-1b, IL-6,
VCAM and EAAT-2 in the L3-L5 spinal cords of pSNL-injured
mice were not affected by intrathecal AMD3100 (all p.0.05;
student’s t test; Figures 3A, D, E, F, H and I).
Effects of intrathecal AMD3100 on pain signaling
pathways in the lumbar spinal cord of pSNL-injured mice
Spinal mitogen-activated protein kinases (MAPKs), phospho-
inositide 3-kinase (PI3K), STAT3 and nuclear factor kappa-light-
chain-enhancer of activated B (NF-kB) pathways were shown to be
significantly activated on POD 7 using PNP models [17–20]. Our
Figure 2. The effects of intrathecal AMD3100 on the development and maintenance of PNP in pSNL-injured mice. The preemptive
intrathecal AMD3100, but not intrathecal saline, increased ipsilateral PWT of pSNL mice for 3 days after the surgery (A), but did not affect contralateral
PWT (B). On POD 7, intrathecal AMD3100 at dosages of 1 mg, 5 mg and 25 mg increased the ipsilateral PWT of pSNL mice for 2, 3 and 3 days,
respectively (C), but did not affect contralateral PWT (D). Results are mean6 SEM (n= 5–12). ***p,0.001 versus the pSNL group at the corresponding
timepoints. ###p,0.001 versus the Saline + pSNL group at the corresponding timepoints. aaap,0.001, ap,0.05, bbbp,0.001, bbp,0.01, bp,0.05,
YYp,0.01 and Yp,0.05 versus the baseline. g = gram, D = day, Hr = hour, 0 = time of intrathecal injection.
doi:10.1371/journal.pone.0104860.g002
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result found that intrathecal AMD3100 in all used dosage
produced analgesic effects on pSNL-injured mice at hour 8 after
the drug injection. Therefore, we harvested lumbar spinal cord
sample from this time-point and detected whether intrathecal
AMD3100 could affect the activation of members of these
pathways. The phosphorylation level of JNK1 (p,0.01; student’s
t test; Figure 4C) and p38 (p,0.05; student’s t test; Figure 4E) and
the expression level of p65 (p,0.05; student’s t test; Figure 4H)
was decreased significantly on the ipsilateral side of the L3-L5
spinal cord segment in pSNL-injured mice with intrathecal
AMD3100 25 mg (n= 8), compared to the saline group (n = 8).
However, the activation (phosphorylation) levels of ERK1, ERK2,
and JNK2 in the L3-L5 spinal cords of pSNL-injured mice were
not affected by intrathecal AMD3100 (all p.0.05; student’s t test;
Figures 4A, B, D, F and G).
Discussion
Although recent immunohistochemistry study has suggested the
involvement of CXCR4 in pain processing in the CNS [10],
central roles of CXCR4 in nociception remain unclear. Therefore,
in order to explore the function of CXCR4 in pain modulation in
CNS, we studied the pharmacological effects of intrathecal
administration of CXCR4 antagonist (AMD3100) on PNP using
a pSNL model. The pSNL model is a widely used PNP model, and
long-lasted mechanical allodynia is induced following partial
sciatic ligation [11]. Our present work employed a single
intrathecal injection of AMD3100 before pSNL surgery or on
POD 7 with similar methods used in antagonism studies of other
chemokine receptors [21,22]. Evidence for the involvement of
central CXCR4 in the initiation of PNP came from the
observation that the pretreatment of AMD3100 led to an
attenuation of pSNL-induced allodynia. Essentially, this CXCR4
antagonist was also effective in alleviating mechanical allodynia
when pSNL-induce neuropathy had been established. The results
indicated that CXCR4 also contribute to the early maintenance of
PNP state. Moreover, the reliability of these behavioral anti-
nociceptive effects was enhanced by the facts the intrathecal
AMD3100 did not impair any motor function.
Previous studies reported analgesic effects of systematic admin-
istration of AMD3100 only lasted for hours [8,10], but the effects
of central administration of AMD3100 as used in our current
study could last for several days. As CXCR4 is widely distributed
on nearly all cell types and plays important roles in the tissue
development [23], systematic (intraperitoneal) administration of
Figure 3. The effects of intrathecal AMD3100 on the production of neuropeptides and pro-inflammatory cytokines, and cellular
adhesion molecules in the ipsilateral L3-L5 spinal cord segment of pSNL-injured mice. Real time PCR revealed that intrathecal AMD3100
decreased mRNA level of SP (B) and increased mRNA level of AM (C) and ICAM (G), but did not affect mRNA levels of CGRP (A), TNF-a (D) and IL-1b (E),
IL-6 (F), VCAM (H) or EAAT-2 (I) at hour 8 after the injection. Results are means 6 SEM (n= 6). *p,0.01, #p and Yp,0.05 versus the saline group.
doi:10.1371/journal.pone.0104860.g003
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CXCR4 antagonist would be of lower nociceptive structure-
specificity and anti-nociceptive efficiency relative to central
(intrathecal) administration of AMD3100 theoretically. Moreover,
intrathecal delivery of AMD3100 is highly specific to spinal cord,
implicating that central (spinal) administration of CXCR4
antagonist for analgesia would be more effective than peripheral
injection. While the effects of AMD3100 on DRG have been
previously reported [3,4,6–8], its spinal effects have not been
studied. Multiple mechanisms would accounts for the anti-
nociceptive effects of intrathecal AMD3100, as CXCR4 is
expressed on neuron, glia and other cell types in the lumbar
spinal cord [9,10]. Therefore, in the current study, we explored its
effects on well-known pain pathways and molecules at the lumbar
spinal cord.
GPCR coupled signaling, including MAPKs, PI3K, STAT3
and NF-kB pathways, are proposed to function in CXCR4
signaling, and these pathways are also activated in the lumbar
spinal cord following peripheral neuropathy [17–20]. As these
pathways are activated by different cell type-specific mechanisms,
antagonism study of intrathecal AMD3100 on these pathways can
explain how CXCR4 signaling works on PNP in the CNS. The
present study found that, among MAPK pathways, intrathecal
AMD3100 downregulated spinal phosphorylation level of JNK1
and p38, but did not affect ERK1, ERK2 or JNK2. Peripheral
neuropathy activates ERK1/2 in neuron, astrocyte and microglia.
pSNL-induced activation of JNK1/2 is restricted to spinal
astrocyte, while, the activation of p38 is restricted to spinal
microglia [17]. This study also uncovered that intrathecal
AMD3100 reduced the spinal expression of p65. The family of
NF-kB transcription factors is associated with neuropathic pain,
and the activation (increase in expression) of these factors is
selectively restricted in spinal glial cells (astrocyte and microglia)
[18,24]. Peripheral neuropathy also activates STAT3 (restricted to
spinal microglia [20]) and AKT (restricted to spinal neuron [19]);
however our present study did not found any effect of intrathecal
AMD3100 on STAT3 or AKT pathways. Therefore, this research
found that, among pain-related CGRP pathways, some pathways
activated in spinal glial cells would account for anti-nociceptive
effects of intrathecal AMD3100.
This research also studied the effects of intrathecal AMD3100
on pain-related molecules. Our study showed that AMD3100
given intrathecally reduced the spinal production of SP and
increased that of AM, but its effects on CGRP were not detectable.
SP is locally expressed by secondary sensory neuron at the lumbar
Figure 4. The effects of intrathecal AMD3100 on pain pathways in the ipsilateral L3-L5 spinal cord segment of pSNL-injured mice.
Western blotting revealed that intrathecal AMD3100 decreased the phosphorylation level of the JNK1 (C), p38 (E) and p65 (H) pathway, but did not
affect the phosphorylation levels of the ERK1 (A), ERK2 (B), JNK2 (D), AKT (F) or STAT3 (G) at hour 8 after the injection. Results are means6 SEM (n= 8).
**p,0.01, #p and Yp,0.05 versus the saline group.
doi:10.1371/journal.pone.0104860.g004
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spinal cord [25], and spinal SP expression is inducible following
neuropathy, implicating that SP may account for the pain
signaling to higher level of nociceptive structure [26]. AM is a
pain-related neuropeptide with partial homology to CGRP, and
recent research with transgenic technology unveiled its central role
in pain processing was more complicated than previously surmised
[27]. Because the presence of pre-synaptic and post-synaptic
CXCR4 receptor implicates the potential interaction of CXCR4
signaling and the release of neurotransmitters [9], our results
verified this hypothesis that neuronal CXCR4 may modulate SP
and AM-mediated synaptic activity in central nociception. TNF-a,
IL-1b and IL-6 are mainly released by spinal glial cells and
contribute to the alteration of pain processing centrally [28].
Spinal production of these cytokines was transiently increased at
early stage following peripheral neuropathy, implicating that these
pro-inflammatory cytokines would be important to the develop-
ment, but not the maintenance, of neuropathic pain [29].
Therefore, our results indicated that effects of intrathecal
AMD3100 on maintenance of PNP did not involve the regulation
of these pro-inflammatory cytokines. Moreover, our study found
that AMD3100 given intrathecally increased the spinal mRNA
level of ICAM. The blood-spinal cord barrier (BSCB) offers a
specialized microenvironment for the cellular constituents of the
spinal cord, and increasing evidence shows that BSCB is involved
in nociception following neuropathic injury [30]. The expression
level of ICAM correlates with the permeability of BSCB and the
infiltration of immune cells to the CNS [31]. Therefore, this result
indicated that central CXCR4 would be involved in the regulation
of the permeability of BSCB and the immune response to PNP at
the spinal cord. Spinal expression of EAAT-2 is decreased with
peripheral neuropahty, and the prevention of downregulated
EAAT-2 expression can potentially be an analgesic target [32].
Nevertheless, this studied did not show the involvement of central
CXCR4 in the regulation of EAAT-2 expression.
In conclusion, this study firstly reports that central administra-
tion of CXCR4 antagonist AMD3100 can attenuate the develop-
ment and the maintenance of PNP after pSNL without any
impairment in motor function. Among well-known pain related
pathways and molecules, the analgesic effects of intrathecal
AMD3100 involve the downregulation of JNK1, p38 and p65
pathways, with the decrease in SP and the increase in AM and
ICAM in the lumbar spinal cord of pSNL-injured mice. This study
is an essential step toward understanding the contribution of
CXCR4-mediated pain processing in CNS, which can lead to
chemokine-targeted analgesia in the future.
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